Optiscan Lodges U.S. FDA 510(k) Submission for InVue

Summary by 6ix AI

This submission follows a recent application for another device, InForm, and demonstrates the maturity of Optiscan's technology platform. The FDA review process will assess the technical and clinical evidence supporting the application, which is crucial for potential commercialization in the U.S. market. CEO Dr. Camile Farah emphasized that this submission brings the company closer to making real-time microscopic imaging available in operating theatres.

Written by 6ix AI from the company’s filing. How 6ix writes summaries